| Olanzapine versus risperidone | Olanzapine versus ziprasidone | Risperidone versus quetiapine | |
|---|---|---|---|
| k (total N) | 1 (80) | 1 (394) | 1 (25) |
| Study ID | VOLAVKA2002 | KINON2006A | CONLEY2005 |
| Diagnostic criteria | DSM-IV | DSM-IV | DSM-IV |
| Selected inclusion criteria | Suboptimal response to previous treatment a | Prominent depressive symptoms | Treatment resistant c |
| Setting | Inpatient | Outpatient | Inpatient |
| Duration of treatment | Medium term: 14 weeks | Medium term: 24 weeks | Medium term: 12 weeks |
| Medication dose (mg/day) | Olanzapine: 10–40mg/day (range) Risperidone: 4–16mg/day (range) | Olanzapine: 10, 15 or 20mg/day (fixed) Ziprasidone: 80, 120 or 160mg/day (fixed) | Risperidone: 4mg/day (fixed) Quetiapine: 400mg/day (fixed) |
Note.
Defined by history of persistent positive symptoms after at least 6 contiguous weeks of treatment with one or more typical antipsychotics at ≥600mg/day chlorpromazine hydrochloride equivalent, and a poor level of functioning over past 2 years.
Defined by a MADRS score≥16 (mild depression) and a score ≥4 (pervasive feelings of sadness or gloominess) on item 2 (reported sadness) of the MADRS.
Defined by: (1) Persistent positive symptoms (≥4 points on 2 of 4 BPRS psychosis items); (2) Persistent global illness severity (BPRS total ≥45 and CG I≥ 4); (3) At least two prior failed treatment trials with two different antipsychotics at doses of ≥600 mg/day chlorpromazine hydrochloride equivalent each of at least 6 weeks’ duration; (4) No stable period of good social/occupational functioning in past 5 years.
From: 10, PHARMACOLOGICAL INTERVENTIONS IN THE TREATMENT AND MANAGEMENT OF SCHIZOPHRENIA
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.